VK2735: Injection and Oral Evidence, Safety and Phase 3 Status
Published
Direct answer: VK2735 is Viking Therapeutics' investigational dual GLP-1/GIP receptor agonist, being studied as an injection and an oral tablet. Its weekly injection produced substantial weight reduction in the published 13-week VENTURE trial. Oral results and maintenance findings come from separate studies and reporting formats. As checked November 21, 2026, both formulations remain in clinical development; a trial result is not an approved prescription product or a dosing recommendation. [1–8]
Key findings
- Two formulations, different evidence: weekly subcutaneous VENTURE has a full peer-reviewed report; VENTURE-Oral has a conference poster and sponsor-reported results in the sources assessed here. [1,3,4]
- Percentage labels matter: the highest injection arm lost 14.7% from baseline; its published placebo-adjusted difference was 13.08 percentage points. Those are different quantities. [1]
- Safety requires more than “mostly mild”: gastrointestinal events, treatment discontinuation and serious events need separate consideration. [1,3]
- Phase 3 is ongoing: VANQUISH evaluates injections; SUNRISE evaluates tablets. The SUNRISE registry records were updated to recruiting on November 16, 2026. [5–8]
- Maintenance is a separate question: retaining a percentage of previously lost weight is not the same as losing that percentage of starting body weight. [9]
This guide organizes the evidence by preparation, population, outcome and source date. It does not rank VK2735 above approved medicines on the basis of unrelated trials, predict a person's weight loss or supply a self-treatment schedule.
What VK2735 is
VK2735 is a development code, not a consumer brand name. The compound acts at receptors for two incretin hormones: glucagon-like peptide-1, abbreviated GLP-1, and glucose-dependent insulinotropic polypeptide, abbreviated GIP. Viking is developing both subcutaneous and oral formulations of the same therapeutic compound. [10]
The receptor description identifies a mechanism; it does not establish interchangeability with another dual agonist. Different molecules and formulations can produce different exposure, tolerability and results. “GLP-1/GIP” should therefore help readers locate the relevant research, not serve as a shortcut for transferring another medicine's label, dose or expected outcome.
The names also identify different research programs. VENTURE refers here to the injection phase 2 study. VENTURE-Oral refers to the tablet study; some sponsor materials also use “VENTURE-2.” VANQUISH-1 and VANQUISH-2 are injection phase 3 studies, while SUNRISE-1 and SUNRISE-2 are oral phase 3 studies. Trial identifiers below are more reliable than similar-sounding program names when matching a result to a formulation. [2,4–8]
For the broader treatment landscape, our GLP-1 evidence guide distinguishes individual products and indications. The dapiglutide reference covers a different GLP-1/GLP-2 strategy; it should not be used as evidence for VK2735.
Human evidence map
| Evidence stream | Population and design | What it can answer | Main limit |
|---|---|---|---|
| Weekly injection VENTURE, NCT06068946 [1,2] | Randomized, blinded, placebo-controlled, 13-week phase 2 study; adults with obesity or overweight and a weight-related condition; diabetes excluded | Short-term weight change and observed safety with the tested injection | Small, short dose-finding study; not a head-to-head comparison or long-term outcomes trial |
| VENTURE-Oral, NCT06828055 [3,4] | Randomized, blinded, placebo-controlled 13-week tablet study; registry enrollment 280 actual | Tablet-specific efficacy and tolerability in the reported cohorts | Conference/sponsor reporting; selected displayed cohorts should not be mistaken for the entire registered population |
| Injection maintenance study [9] | Sponsor-reported randomized study with 21-week induction and 12-week maintenance phases | Weight retained after transition to less frequent injection regimens | Exploratory, selected post-induction population and short maintenance window |
| VANQUISH-1 and VANQUISH-2 [5,6] | Phase 3 injection studies, without and with type 2 diabetes, respectively | Planned longer-term benefit and risk assessment | Ongoing; no posted results in retrieved registry records |
| SUNRISE-1 and SUNRISE-2 [7,8] | Phase 3 oral studies, without and with type 2 diabetes, respectively | Planned 68-week tablet efficacy and safety | Recruiting is a study status, not a positive outcome |
Injection results: baseline change versus placebo-adjusted change
The full VENTURE publication reports 176 randomized participants, 175 in the safety population and 174 in the modified intention-to-treat efficacy population. At week 13, modeled weight change ranged from −9.1% to −14.7% across active arms versus −1.7% with placebo. The largest published difference from placebo was −13.08 percentage points. [1]
The efficacy analysis required treatment plus an evaluable baseline and post-baseline weight. It used repeated-measures modeling, with assessments after treatment discontinuation plus nine days set to missing. That is not equivalent to measuring every randomized person's eventual outcome regardless of treatment persistence. [1]
For a reader, this changes how the headline should be used. “Up to” selects one arm; it does not describe every participant. A group mean is not an individual guarantee. Subtracting rounded headline percentages may give an approximate contrast, but the report's modeled treatment comparison is the appropriate figure to cite when describing the trial's result.
Participants also received lifestyle guidance. The experiment evaluates assignment to the study treatment in that setting, rather than a promise that a molecule alone causes the same change under any circumstances. A 13-week trajectory cannot be extended linearly into an annual forecast. The observation that weight had not plateaued by the last treatment visit leaves later efficacy to be measured, not assumed.
Oral results: a separate dataset
The May 2026 ECO poster presents tablet results with a highest displayed arm showing −12.2% weight change at week 13 versus −1.3% for placebo. Viking's accompanying report gives a placebo-adjusted difference of −10.9 percentage points for that arm. These are tablet findings, not a second analysis of the injection trial. [3,16]
There is an important denominator boundary. The oral registry records 280 participants across seven assignments. The poster's main outcome displays show six groups, with efficacy denominators of 40, 40, 40, 38, 39 and 39. We do not silently convert that displayed set into the complete registered population or infer an unreported arm's outcome. [3,4]
A conference poster can provide useful original data while leaving less room than a full report for explaining missingness, analytical choices and all randomized groups. Its evidence should retain that reporting level. “Completed” in the registry does not mean a full results table is posted there; the retrieved record has no posted results. [4]
The injection and oral percentages do not establish that one formulation is superior. Those studies were not a randomized comparison of tablets against injections. Different treatment exposure, escalation, analysis sets and persistence can affect apparent differences. Convenience is also a separate outcome: an oral route may be attractive, but improved adherence or better long-term results need to be demonstrated.
Safety: severity, seriousness and persistence
The published injection trial recorded serious adverse events in eight safety participants. Two events in one person—atrial fibrillation and dehydration—were judged possibly and probably related to treatment, respectively. One death from head trauma after a fall was assessed as unrelated to study drug. Gastrointestinal events were common. [1]
Those findings make it inappropriate to summarize the study as “no serious events.” Equally, an investigator's assessment of possible or probable relationship is not proof that every event in the study was caused by the drug. Causality, severity and regulatory seriousness are different dimensions.
The oral poster likewise reports gastrointestinal effects and drug-related serious events, including angioedema/urticaria, dehydration and nausea/vomiting. Its statement that most drug-related events were mild or moderate does not mean most participants had no adverse effects, and it does not exclude a clinically important minority. [3]
| Oral poster measure [3] | Placebo, safety n=40 | Highest displayed tablet arm, safety n=40 | Interpretation |
|---|---|---|---|
| TEAE leading to treatment discontinuation | 5/40 (13% rounded) | 12/40 (30%) | Stopped treatment; this is not the number who left all study follow-up |
| TEAE leading to study discontinuation | 1/40 (3% rounded) | 0/40 | Different endpoint; people may stop medication and remain observed |
These are selected arm-specific figures from the poster, not pooled tablet risks or a comparison with the injection. The efficacy denominator for that displayed active arm is 39, while its safety denominator is 40. The difference is a reason to retain the population labels, not to choose whichever denominator makes a percentage look more favorable.
The most useful safety questions are practical: how often did people experience an event, how severe was it, was it serious, did it lead them to stop treatment, and how long were they observed? “Mostly mild” answers only part of that set. Larger and longer studies can reveal risks that a short phase 2 study cannot characterize reliably. [11] Our peptide safety guide explains these evidence limits across products.
Maintenance: what a retained-weight-loss percentage means
Viking's September 22, 2026 topline release describes a separate study in which participants first underwent a weekly injection induction period, then entered a 12-week maintenance phase. In the reported combined groups, every-other-week dosing retained 90% of initial weight loss, monthly dosing retained 85%, and the placebo transition group retained 61%. [9]
Those percentages refer to previously lost weight. A simplified arithmetic example illustrates the denominator: if someone lost 20 units of weight and later retained 85% of that loss, they retained a 17-unit reduction and regained three units. They did not lose 85% of their original body weight. This example explains the metric; it is not a prediction for a patient.
The release also describes an excluded outlier in one monthly efficacy cohort. That cohort's result changes when the participant is included. We retain the release's analysis qualification rather than presenting its most favorable alternative as the definitive result. [9]
This maintenance window does not establish that people can start VK2735 monthly, substitute tablets milligram for milligram or follow a self-designed transition. The maintenance question begins after an induction period in a selected trial population. Its result must be interpreted within that pathway. Evidence that a regimen preserves some prior loss also differs from evidence of additional loss, sustained function or fewer cardiovascular events.
Phase 3 status as checked November 21, 2026
The table uses the current official registry API records retrieved for this review. Search snippets can lag behind those records. In particular, older SUNRISE descriptions still say “not yet recruiting,” while both retrieved November 16 updates say recruiting. Neither status implies that results have been established. [5–8]
| Trial and formulation | Retrieved status and last update | Primary weight endpoint | Estimated enrollment and timing |
|---|---|---|---|
| VANQUISH-1, injection; NCT07104500 [5] | Active, not recruiting; November 24, 2025 | 78 weeks | 4,500 estimated; primary completion July 2027 estimated |
| VANQUISH-2, injection; NCT07104383 [6] | Active, not recruiting; April 7, 2026 | 78 weeks | 1,100 estimated; primary completion July 2027 estimated |
| SUNRISE-1, tablet; NCT07868835 [7] | Recruiting; November 16, 2026 | 68 weeks | 560 estimated; primary completion July 2028 estimated |
| SUNRISE-2, tablet; NCT07868939 [8] | Recruiting; November 16, 2026 | 68 weeks | 560 estimated; primary completion October 2028 estimated |
Registry enrollment targets are not necessarily final actual counts. For example, Viking's October update describes roughly 1,000 enrolled in VANQUISH-2, while its retrieved registry still carries an estimated target of 1,100. Those statements have different labels and dates; this guide does not relabel the registry target as an observed enrollment total. [6,12]
The developer announced initiation of the oral phase 3 program on October 14. That announcement and the later recruiting updates are complementary dated records, not evidence that a trial already succeeded. The same announcement corrected an earlier reference to “weekly oral” maintenance: the intended oral option was daily, with less frequent schedules referring to injections. [13] This correction is another reason not to copy a schedule from an isolated headline.
What remains unknown
The checked evidence does not settle a direct comparison against another incretin medicine, a tablet-versus-injection choice for an individual, uncommon long-term harms or a dependable commercial launch date. It also does not establish a cardiovascular-event benefit from improvements in weight, blood pressure or modeled risk.
The November ObesityWeek materials include exploratory cardiometabolic analyses and VANQUISH-2 baseline characteristics. Baseline descriptions tell readers who entered a study; they are not treatment outcomes. Likewise, a model predicting future cardiovascular risk is not an observed reduction in heart attacks or deaths. [14]
Animal and laboratory findings should stay separate from these human results. The developer describes preclinical work supporting its program, but this guide's clinical assessment rests on the human sources above. A receptor experiment or mouse response cannot fill a missing human comparison or erase a human adverse-event signal. FDA similarly distinguishes preclinical investigation from clinical research. [10,11]
Reader questions
Is VK2735 approved or available as a routine prescription?
The assessed program remains investigational, with ongoing phase 3 studies. No approved VK2735 prescribing label was identified in the checked sources. Trial participation and ordinary prescription access are different pathways. A seller's research label does not establish equivalence to the trial preparation. FDA's general guidance explains why identity and manufacturing quality belong to product-specific review. [5–8,15]
Is VK2735 another name for tirzepatide?
No. The shared dual-receptor description does not make different compounds interchangeable. Evidence for one product cannot supply another product's approved indication, exposure or dose. Match the molecule and formulation before comparing any results.
Do the phase 2 percentages predict what I would lose?
No. They are group results under specified study conditions and analysis assumptions. Your own outcome cannot be read from the best-performing arm or a responder percentage. A matched clinical population and a measured endpoint are starting points for interpretation, not an individual forecast.
Does “no plateau” mean weight loss continues indefinitely?
No. It describes the observed treatment period. It neither establishes indefinite loss nor predicts when a later plateau will occur. Longer follow-up must answer that question.
What evidence would change this assessment?
Completed phase 3 reports with clear analysis populations, treatment persistence, missing-data methods and safety follow-up would strengthen the assessment. A direct randomized comparison could answer comparative questions that separate placebo-controlled trials cannot. Maintenance evidence should distinguish the induction population, the transition population, retained loss and additional loss. Transparent reporting of all randomized arms would help reconcile the oral registry and selected poster displays.
Editorial methods and references
Prepared by the Peptide Dossier Editorial Team with AI assistance under the editorial policy. Sources checked November 21, 2026. This is a targeted editorial synthesis, not a systematic review or clinician-reviewed treatment recommendation. We read the full original injection report, the accessible original oral-poster text and official registry API records, and attributed developer reports for maintenance and program updates. No personal treatment experience or validated self-treatment protocol is claimed.
- Bays HE et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity. 2026;34:537–549. First published January 8, 2026; PMID 41508550.
- ClinicalTrials.gov: NCT06068946, VENTURE injection phase 2. Completed; 176 actual participants; registry last updated February 12, 2025.
- Hedges PJ et al. Treatment with Oral VK2735: VENTURE-Oral study poster, ECO May 12–15, 2026. Original sponsor-supported conference poster.
- ClinicalTrials.gov: NCT06828055, VENTURE-Oral. Completed; 280 actual participants; last updated October 6, 2025.
- ClinicalTrials.gov: NCT07104500, VANQUISH-1. Retrieved current official record; dates and estimates distinguished above.
- ClinicalTrials.gov: NCT07104383, VANQUISH-2. Retrieved current official record; estimated target is not an actual count.
- ClinicalTrials.gov: NCT07868835, SUNRISE-1. Recruiting; record updated November 16, 2026.
- ClinicalTrials.gov: NCT07868939, SUNRISE-2. Recruiting; record updated November 16, 2026.
- Viking: Maintenance-study topline results, September 22, 2026. Developer report, not represented as a full peer-reviewed publication.
- Viking: VK2735 development overview. Mechanism and formulation identity; historical sections are not treated as the latest trial status.
- FDA: Step 3, Clinical Research. Clinical versus preclinical evidence and study-phase purposes.
- Viking: Third-quarter program update, October 28, 2026. Attributed development and enrollment statements.
- Viking: Oral phase 3 initiation and schedule correction, October 14, 2026. Includes correction to earlier oral-maintenance wording.
- Viking: ObesityWeek clinical data update, November 15, 2026. Exploratory and baseline presentations distinguished from clinical outcomes.
- FDA: Concerns About Unapproved Drugs. General product-review context.
- Viking: ECO oral-study results, May 12, 2026. Developer's original report supplies the oral placebo-adjusted estimate and displayed efficacy denominators.